47 results about "Obstructive chronic bronchitis" patented technology

The present invention discloses a traditional Chinese medicine composition for treating chronic bronchitis combined with emphysema. The composition is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 15-25 parts of astragalus, 20-30 parts of prepared rehmannia, 18-22 parts of schisandra, 15-25 parts of pinellia, and 20-30 parts of poria. The composition nourishes the liver, spleen, and kidneys, reduces stomach qi, purges the lungs, and relieves asthma, promotes diuresis and reduces swelling, promotes blood circulation and removes blood stasis, regulates qi and resolves phlegm, and is suitable for treating chronic bronchitis combined with emphysema. The present invention also discloses a preparation method and use thereof.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The invention relates to the technical field of traditional Chinese medicine preparations and atomization medicine delivery, in particular to a method for treating chronic bronchitis based on Tibetan medicine Bunjinjian San, which comprises the following steps: S1, drying Bunjinjian San raw medicine at low temperature, and carrying out superfine grinding to obtain raw medicine micro powder; s2, removing resin and grease impurities; s3, carrying out vacuum concentration on the obtained filtrate; s4, treating the concentrated extract through an ultrafiltration membrane; s5, preparing the clarified extracting solution into atomized liquid; s6, medicine aerosol is formed through ultrasonic oscillation; s7, guiding the chronic bronchitis patient to inhale the drug aerosol; s8, after all the inhalation treatment courses are completed, a treatment conclusion report is obtained. According to the present invention, the particle size controllable Bunjinjian aerosol is prepared through the continuous purification-clarification-sterilization-atomization process, such that the targeted lower respiratory tract drug delivery is achieved, the preparation quality and the equipment smoothness are ensured, the local treatment effect is improved, and the whole body side effect is reduced.

1. The name of the design product: water negative ion device. 2. The use of the design product: for air purification and disinfection, auxiliary treatment of chronic bronchitis and non-acute insomnia. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

This invention relates to a guinea pig model of chronic obstructive pulmonary disease (COPD) with chronic bronchitis, its preparation method, and its application. Specifically, this invention provides a guinea pig model of COPD with chronic bronchitis, established by subjecting guinea pigs to at least two intratracheal infusions of lipopolysaccharide (LPS) combined with repeated exposure to cigarette smoke. This results in the guinea pigs exhibiting pathophysiological characteristics consistent with those of COPD with chronic bronchitis in terms of cough sensitivity, airway inflammation, airway hypersecretion, lung function, and histopathology. This lays a solid foundation for in-depth research and drug screening of COPD with chronic bronchitis.

1. The name of the design product: lung instrument. 2. The use of the design product: for the auxiliary treatment of chronic bronchitis, chronic obstructive emphysema, bronchial asthma, and chronic pulmonary heart disease and other diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The present invention relates to novel pyrrolidinium compounds, stereoisomers, hydrates or solvates thereof, which exhibit excellent binding capacity and antagonistic activity to muscarinic receptors, in particular muscarinic M3 receptors. The compounds of the present invention are useful in the treatment of muscarinic acetylcholine receptor mediated diseases, such as hyperhidrosis, excessive salivation, chronic obstructive pulmonary disease, chronic bronchitis, asthma, rhinitis, urinary incontinence, overactive bladder, gastroesophageal reflux disease, irritable bowel syndrome, and the like.

A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C—S—C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.

The invention discloses a Tibetan medicine Banjiaojiaopian pellet preparation, which comprises raw materials and auxiliary materials, the raw materials comprise the following components: gentiana algida, agilawood, choerospondias axillaris, white sandalwood, myristica fragrans, tabasheer, alpine horseradish, costus root, fructus chebulae, fructus terminaliae billericae, emblic leafflower fruit, tinospora sinensis merr, corydalis impatiens, clove and liquorice, and the auxiliary materials comprise an adhesive and a filler microcrystalline cellulose; the technological parameters for preparing the pellet preparation by adopting centrifugal granulation are as follows: the liquid spraying speed is 50ml / min, the number of revolutions of a turntable is 30r / min, and the air inlet temperature is 75 DEG C. Compared with traditional pills, the pellet preparation provided by the invention has the advantages of high dissolution rate, obviously improved bioavailability, reliable drug effect, accurate taking dosage, stable quality, low cost, good treatment effect, fine production process, good reproducibility, good quality controllability, high industrial production efficiency and wide application range.

The invention relates to the technical field of traditional Chinese medicine or food, and provides an application of a traditional Chinese medicine composition in preparation of a product for relieving and / or preventing lung heat and fluid impairment syndrome, the composition comprises the following components: orange peel, honeysuckle, mint, forsythia leaf, reed rhizome, platycodon grandiflorum, boat-fruited sterculia seed, lily, momordica grosvenori and almond. The composition provided by the invention has a remarkable effect of preventing chronic upper respiratory infection, a remarkable effect of treating oral ulcer caused by excessive internal heat, a remarkable effect of treating chronic pharyngolaryngitis and a remarkable effect of treating chronic bronchitis, and can be used for preparing products for relieving and / or preventing and treating lung heat and fluid impairment syndromes.

The present disclosure relates to methods of treatment of asthma, COPD, Asthma-COPD Overlap Syndrome (ACOS), and chronic bronchitis, or a combination thereof, with formulations comprising (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl)-3-oxopropanenitrile.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

Systems and methods involve abrading a patient lung airway wall to reduce mucus production therein. Exemplary techniques include rotationally and / or linearly oscillating an abrasive material against the airway wall so as to damage mucus producing tissues, for example by removing goblet cells, while destroying less than the entire airway wall. The abrasive material may be present on the surface of an expandable balloon body or another expandable device, which can be delivered to the patient treatment site via a bronchoscope. In some cases, the abrasion techniques can cause cell damage or death at a controlled or predetermined tissue depth.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The invention relates to the technical field of tracheitis treatment, in particular to a spittoon asthma tablet and a preparation method thereof. The tablets for treating asthma caused by excessive phlegm comprise 60-80 parts of radix sophorae flavescentis extract, 5-10 parts of golden cypress fruit oil, 20-30 parts of filler, 1-2 parts of lubricant, 5-10 parts of lily, 2-5 parts of fried almond and 0.5-1 part of liquorice. The sophora flavescens extract, the cortex phellodendri oil and the lily have a synergistic effect, and after the sophora flavescens extract, the cortex phellodendri oil and the lily are combined, cough and asthma such as chronic tracheitis or bronchitis can be remarkably treated, and the effect is remarkable.

The invention discloses a traditional Chinese medicine compound preparation and a preparation method thereof. The compound preparation is prepared from, by weight, 6-10 parts of herba ephedrae, 9-12 parts of semen armeniacae amarae, 6-9 parts of radix platycodonis, 9-15 parts of cortex mori, 6-10 parts of fritillary bulb, 10-15 parts of thorny elaeagnus leaf, 12-18 parts of herba ardisiae japonicae, 9-12 parts of folium eriobotryae, 15-30 parts of herba houttuyniae, 6-10 parts of caulis bambusae in taeniam, 6-9 parts of pericarpium citri reticulatae, 3-6 parts of spearmint and 3-6 parts of radix glycyrrhizae. The traditional Chinese medicine compound preparation disclosed by the invention creatively integrates the three effects of diffusing the lung, dispelling wind, clearing heat, reducing phlegm, moistening dryness and relieving asthma, and has a good effect in the aspect of treating exogenous cough with symptoms of acute and chronic bronchitis and cough after cold.

The invention belongs to the field of biological medicine, and particularly relates to application of small molecules in prevention and treatment of acute and chronic bronchitis, N-dodecyl methylamine can significantly prolong cough latency time of mice suffering from acute or chronic bronchitis, significantly reduce cough times of the mice suffering from acute or chronic bronchitis, and significantly improve cough latency time of the mice suffering from acute or chronic bronchitis. The micromolecule can be used as a medicine for treating or relieving acute or chronic bronchitis, and a new choice is provided for clinical treatment of bronchitis; double distilled water suspension small molecules are adopted for administration, the method is simple, convenient and rapid, and a remarkable effect is achieved. The micromolecule can obviously reduce the cough frequency and cough latency time of acute and chronic bronchitis, and has a good clinical application prospect.

The present disclosure relates to methods of treatment of asthma, COPD, Asthma-COPD Overlap Syndrome (ACOS), and chronic bronchitis, or a combination thereof, with formulations comprising (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl)-3-oxopropanenitrile.

The present application relates to a use of L-erodostatin, and more particularly, to a use of erodostatin in preparation of a medicament, wherein the medicament is used for one or more of mucus dissolution and expectoration, treatment or improvement of upper respiratory inflammation, treatment or prevention of acute or chronic bronchitis, treatment or prevention of cough, treatment or prevention of asthma, treatment or prevention of pneumonia, prevention of pulmonary fibrosis, prevention of alveolar destruction, treatment or prevention of chronic obstructive pulmonary disease, enhancement of resistance to bacteria causing upper respiratory infection, and improvement of side effects caused by smoking. The present application can rapidly increase the blood concentration of metabolically active Met-I of erodostatin, exhibit a rapid and excellent effect, and has no toxicity, and has the same effect as the existing racemic compound at a smaller amount. In addition, since the amount used can be less than that of the existing racemic compound, the present application has an effect of reducing potential side effects.

The invention belongs to the technical field of medicines, and particularly discloses a novel 5-7-5 ring system beta acid compound, a preparation method thereof and application of the compound in preparation of anti-inflammatory drugs. The novel 5-7-5 ring system beta acid compound provided by the invention is obtained by separation in nature for the first time, and can be used for preparing medicines for treating inflammation-related diseases, including but not limited to chronic bronchitis, systemic lupus erythematosus, psoriatic arthritis, retinitis, neurological inflammation, rheumatoid arthritis and the like.

The present invention relates to novel pyrrolidinium compounds, stereoisomers thereof, hydrates thereof, or solvates thereof, which exhibit excellent binding ability and antagonistic activity to muscarinic receptors, particularly muscarinic M3 receptors. [Solution] The compounds of the present invention are useful in treating muscarinic acetylcholine receptor-mediated diseases such as hyperhidrosis, excessive salivation, chronic obstructive pulmonary disease, chronic bronchitis, asthma, rhinitis, urinary incontinence, overactive bladder syndrome, gastroesophageal reflux disease, and irritable bowel syndrome.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and particularly discloses a cough and asthma patch and a preparation method thereof. The cough and asthma patch is prepared from active ingredients and a matrix, the active ingredients are prepared from folium eriobotryae, almonds, elaeagnus pungens, actinidia chinensis roots, thyme, polygala japonica, elephantopus scaber, gynura bicolor, veronica didyma, borneol and mentholum, and the matrix is bionic polymeric gel. The preparation method comprises the following steps: S1, preparing the extract; s2, colloid melting: melting the bionic polymer gel; s3, mixing to prepare paste: adding the extract obtained in S1, borneol and mentholum into the molten colloid obtained in S2, and stirring and mixing; and S4, forming. The cough and asthma patch can be used for relieving cough and asthma symptoms caused by asthma and chronic bronchitis, and has the advantages of being rapid in effect taking and lasting in medicine effect; in addition, the preparation method of the cough and asthma patch has the advantages of improving the transfer rate of the active ingredients, the homogeneity of the paste and the low-temperature stability.

The invention relates to a traditional Chinese medicine composition for relieving cough and reducing sputum and a preparation method thereof, and the traditional Chinese medicine composition for relieving cough and reducing sputum is prepared from the following raw materials in parts by weight: 9-11 parts of radix peucedani, 9-11 parts of platycodon grandiflorum, 7-9 parts of ginger bamboo shavings, 8-10 parts of tabasheer and 9-15 parts of bryozoatum. According to the preparation method, the traditional Chinese medicine composition is prepared into granules, and the granules have a good treatment effect on patients suffering from thick expectoration, chest distress and reversed flow of qi due to phlegm-heat obstructing lung of chronic bronchitis.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The invention discloses a budesonide modified compound, a pharmaceutical composition and application of the budesonide modified compound, the budesonide modified compound is a compound shown in a formula (I) or a salt of the compound shown in the formula (I), deposition of the budesonide modified compound in the oropharynx part and the throat part is little, and therefore adverse reactions can be reduced, and the budesonide modified compound can be used for preparing medicines. The pharmaceutical composition can be used for treating glucocorticoid-dependent or non-dependent bronchial asthma or asthmatic chronic bronchitis, and can be administered through any proper administration route according to clinical requirements.

1. The name of this design product: Water negative ion health care machine. 2. Purpose of the product with this design: used for purifying and disinfecting the air, and as an auxiliary treatment for chronic bronchitis and non-acute insomnia. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The invention relates to the technical field of medicinal and edible preparations, and particularly provides a medicinal and edible compound preparation as well as a preparation method and application thereof. The medicinal and edible compound preparation comprises the following components: folium eriobotryae, green kumquat, momordica grosvenori, ginger, lily, radix polygonati officinalis, tangerine, guarana extract, clove, natural menthol and erythritol. All the components of the medicinal and edible homologous compound preparation have a synergistic effect, clinical symptoms such as cough, expectoration, dry throat and wheeze of chronic bronchitis can be relieved, and therefore a product suitable for relieving the symptoms of chronic bronchitis is provided.

The utility model discloses a kind of metal frame processing anti-deviation welding equipment, including welding frame, the inside movable mounting of welding frame has reciprocating screw rod, the both sides of reciprocating screw rod are provided with guide vane, the inside movable of welding frame is provided with transmission seat, transmission seat is fixed with welding gun and is inserted in the inside, the end outer side of welding gun is installed with negative pressure hopper, negative pressure hopper includes the fixed disc installed in the end outer side of welding gun, the outside of fixed disc is covered with smoke suction disc, smoke suction disc end is fixedly provided with negative pressure pipe.The metal frame processing anti-deviation welding equipment, smoke suction disc is wide in front and narrow in back, the front end of front width can expand smoke capture range, form larger negative pressure adsorption area near welding gun, effectively cover the smoke diffusion range generated when welding;Reduce workshop smoke escape;Avoid the situation that staff long-term inhalation can cause welder pneumoconiosis, chronic bronchitis, emphysema and other respiratory diseases.

The invention discloses a cold region chronic obstructive pulmonary disease risk prediction method, electronic equipment and a storage medium. The cold region chronic obstructive pulmonary disease risk prediction method comprises the steps of obtaining conventional indexes of a person to be predicted; and inputting the conventional indexes into a preset COPD risk prediction model so as to predict and display the disease risk of the to-be-predicted person. Wherein the conventional indexes comprise age, smoking condition, drinking condition, chronic bronchitis and emphysema history, airflow blocking condition, average diastolic pressure, heart rate and BMI. The conventional indexes can be obtained without depending on expensive special equipment (such as imaging equipment) or complex biomarker detection, so that the data acquisition cost and the operation difficulty are greatly reduced. The preset COPD risk prediction model is constructed based on an XGBoost model and a Logistic Regression model, so that efficient and accurate COPD disease risk prediction can be realized, and the applicability of the model can be improved.